Proteins resulting from expression of recombinant DNA (rDNA), within living cells, are known as recombinant proteins. rDNAs are DNA molecules that are formed by laboratory procedures of genetic recombination, to bring genetic material together from multiple sources. DNA sequences used for constructing recombinant DNA molecules originate from any species. If the DNA sequences do not occur in nature, they can be created through chemical synthesis of DNA, further incorporating them into recombinant molecules.
Read Report Overview:
After cell engineering and genetic engineering technology, recombinant protein, which is constructed from the creature body, is now at the forefront of biotechnology production. Recombinant protein technology has become the standard, with current shifts in focus from bulk production method to post-production techniques, promising enhanced stability and delivery.
Recombinant protein is highly effective, and plays an indispensable role in treatment of certain diseases, such as hemophilia (excluding blood coagulation factor that has an extremely limited source). Most of the recombinant protein drugs used are derived from human proteins, or, mutants of human proteins, for compensating functional proteins in vivo defects, or, to increase protein function in a body. This renders recombinant proteins with a significantly higher safety than small molecules, leading towards a higher approval rate.
Ask for Country Specific Data-
Clinical trial period for recombinant protein is shorter as compared to small molecule drugs. This further helps in enhancing the patient protection, providing pharmaceutical companies with longer exclusive sales time. These factors have fuelled the development as well as demand for recombinant protein. Recombinant proteins are targeted at major diseases including endocrine diseases, cardiovascular diseases, cancer, and viral diseases. Moreover, the global market for recombinant proteins has larger extension space.
Few approval drugs are available in the recombinant protein market, with no substitute products in therapeutic areas. However, owing to higher financial barriers, and technical barriers, recombinant proteins are subject to high costs. Replicating recombinant proteins is a more difficult task than that of small molecule chemicals. Fact.MR’s report projects the global market for recombinant protein to expand at an average CAGR during the forecast period (2017 to 2022). The market is estimated to account for nearly US$ 460 Mn revenues by 2022-end.
Get market alerts-
North America to Remain Dominant in the Market
North America will continue to retain its dominance in the global recombinant protein market, with sales projected to reach nearly US$ 150 Mn by 2022-end. Europe is estimated to be the second most lucrative market for recombinant protein throughout the forecast period. The market in Middle East & Africa (MEA) is anticipated to witness a sluggish expansion through 2022.
Recombinant proteins factoring molecular growth will remain the most lucrative product in the market, followed by checkpoint regulators. In addition, sales of growth factors, and cytokines are poised to exhibit similar CAGRs through 2022. However, sales of chemokines are estimated to register the fastest expansion through 2022. Demand for enzymes & inhibitors will continue to be sluggish throughout the forecast period.
Although academic & research institutes are expected to remain the largest end-users of recombinant proteins in terms of revenues, sales in biopharmaceutical companies will register the highest CAGR compared to all the other end-user segments through 2022. Revenues from sales of recombinant proteins in academic & research institutes will account for over one-third market share during 2017 to 2022.